Vis enkel innførsel

dc.contributor.authorErga, Aleksander Hagen
dc.contributor.authorMaple-Grødem, Jodi
dc.contributor.authorAlves, Guido Werner
dc.date.accessioned2022-06-20T11:02:05Z
dc.date.available2022-06-20T11:02:05Z
dc.date.created2022-05-23T09:17:09Z
dc.date.issued2022-02
dc.identifier.citationErga, A.H., Maple-Grødem, J., Alves, G.W. (2022) Cannabis use in Parkinson’s disease—A nationwide online survey study. Acta Neurologica Scandinavica, 145 (6), 692-697.en_US
dc.identifier.issn0001-6314
dc.identifier.urihttps://hdl.handle.net/11250/2999556
dc.description.abstractObjectives The aim of this study was to investigate the frequency of use, attitudes toward, and experiences with cannabis and cannabis-related products among people with Parkinson's disease (PwP) living in Norway. Methods Between February and August 2021, PwP and their caregivers were invited to participate in an anonymous online survey study on cannabis use. N = 530 PwP completed the 24-item survey collecting data on the participants’ history of cannabis use, perceived benefits and adverse effects of cannabis use, and expectations toward health care professionals. N = 108 caregivers completed a brief survey detailing their experience with cannabis use. Results A total of 59 (11.3%) of PwP reported previous or current use of cannabis, compared to 7 (6.6%) of caregivers. Cannabis use was associated with increased disease duration, but not age or gender. Improvement in motor function (69.5%), sleep (52.5%), and pain (37.3%) was the most frequently perceived benefits of cannabis use, with benefits more frequently reported by current than previous users. While half (50.8%) of cannabis users had sought advice from a health care professional regarding cannabis use, only 55 (19.9%) of non-users with an interest in cannabis use had discussed the topic with health care professionals. Principal barriers for discussing cannabis use with health care professionals are discussed. Conclusions One in 20 PwP reports cannabis use, and non-users report widespread interest in cannabis. The use of cannabis is often not reported and unknown for health care professionals, arguing for a vigilant approach to non-prescribed cannabis use in clinical follow-up of PwP.en_US
dc.language.isoengen_US
dc.publisherJohn Wiley & Sons Ltd.en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.subjectParkinsonen_US
dc.subjectcannabisen_US
dc.subjectdelta-9-tetrahydrocannabinolen_US
dc.titleCannabis use in Parkinson’s disease—A nationwide online survey studyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2022 The Authorsen_US
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Nevrologi: 752en_US
dc.source.pagenumber692-697en_US
dc.source.volume145en_US
dc.source.journalActa Neurologica Scandinavicaen_US
dc.source.issue6en_US
dc.identifier.doi10.1111/ane.13602
dc.identifier.cristin2026328
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal